Improving prediction and care for people with chronic kidney disease worldwide
Chronic Kidney Disease Prognosis Consortium (CKD-PC)
['FUNDING_R01'] · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · NIH-11143943
This global effort brings together many health studies to improve how doctors predict kidney disease outcomes and guide care for adults with chronic kidney disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NEW YORK UNIVERSITY SCHOOL OF MEDICINE (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11143943 on ClinicalTrials.gov |
What this research studies
You should know that researchers are combining data from hundreds of health studies across many countries to find what best predicts CKD progression and complications. They will run centralized analyses and modern meta-analysis methods to test and refine risk calculators and staging across different regions and patient groups. The team will compare different ways of measuring kidney function (including creatinine and cystatin C) and study links between CKD and heart problems, infections, cancer, frailty, and dementia. The findings are meant to help doctors and guideline groups decide when to test and how to estimate risk for patients like you.
Who could benefit from this research
Good fit: Adults with chronic kidney disease or reduced kidney function, especially those already followed in clinical cohorts or registries and willing to allow use of their health records or samples, are the most relevant participants.
Not a fit: People without kidney disease or those looking for an experimental treatment for immediate symptom relief are unlikely to get direct benefit, since this project focuses on prediction, measurement, and guideline development rather than testing new therapies.
Why it matters
Potential benefit: If successful, this work could give patients clearer risk scores and testing guidance that help catch worsening kidney disease earlier and tailor care more effectively.
How similar studies have performed: Previous phases of the CKD Prognosis Consortium and other large cohort studies have already improved CKD staging and risk tools, though questions remain about global equation changes and broader use of cystatin C.
Where this research is happening
NEW YORK, UNITED STATES
- NEW YORK UNIVERSITY SCHOOL OF MEDICINE — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CORESH, JOSEF — NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- Study coordinator: CORESH, JOSEF
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers